Skip to main content
SpringerLink
Log in

CHRONIC MYELOGENOUS LEUKEMIA

Eutos long-term survival score discriminates different Sokal score categories in chronic myeloid leukemia patients, showing better survival prediction. Analysis of the GIMEMA CML observational study

  • Correspondence
  • Published:
Leukemia Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Pfirrmann M, Clark RE, Prejzner W, Lauseker M, Baccarani M, Saussele S, et al. The EUTOS long-term survival (ELTS) score is superior to the Sokal score for predicting survival in chronic myeloid leukemia. Leukemia. 2020;34:2138–49.

    Article  Google Scholar 

  2. Pfirrmann M, Baccarani M, Saussele S, Guilhot F, Cervantes F, Ossenkoppele G, et al. Prognosis of long-term survival considering disease-specific death in patients with chronic myeloid leukemia. Leukemia. 2016;30:48–56.

    Article  CAS  Google Scholar 

  3. Hochhaus A, Baccarani M, Silver RT, Schiffer C, Apperley JF, Cervantes F, et al. European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. Leukemia. 2020;34:966–84.

    Article  CAS  Google Scholar 

  4. Molica M, Canichella M, Alunni Fegatelli D, Colafigli G, Massaro F, Latagliata R, et al. The Eutos long-term survival score accurately predicts the risk of death in chronic myeloid leukaemia patients treated outside of clinical trials. Am J Hematol. 2017;92:e661–e664.

    Article  Google Scholar 

  5. Geelen IGP, Sandin F, Thielen N, Janssen JJWM, Hoogendoorn M, Visser O, et al. Validation of the EUTOS long-term survival score in a recent independent cohort of “real world” CML patients. Leukemia. 2018;32:2299–303.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Translational and Precision Medicine, Az. Policlinico Umberto I-Sapienza University, Rome, Italy

    Massimo Breccia

  2. Hematology Unit, Az Ospedaliero Universitaria Città’ della Salute e della Scienza, Torino, Italy

    Patrizia Pregno

  3. Institute of Hematology “L. and A. Seràgnoli”, Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, “S. Orsola-Malpighi” Hospital, Bologna, Italy

    Fausto Castagnetti

  4. Department of Medicine, Section of Hematology, University of Verona, Verona, Italy

    Massimiliano Bonifacio

  5. Division of Hematology and BMT, Department of Medical Area, University of Udine, Udine, Italy

    Mario Tiribelli

  6. Hematology Unit, AOU Careggi, University of Florence, Florence, Italy

    Antonella Gozzini

  7. Division of Hematology, Azienda Ospedaliero Universitaria Ospedali Riuniti Ancona, Ancona, Italy

    Anna Rita Scortechini

  8. Hematology Unit, Federico II University of Naples, Napoli, Italy

    Luigiana Luciano

  9. Hematology Unit, A.O. Bianchi-Melacrino-Morelli, Reggio Calabria, Italy

    Bruno Martino

  10. Hematology Section, Ferrarotto Hospital, Catania, Italy

    Fabio Stagno

  11. Department of Medical Sciences and Public Health, University of Cagliari, Businco Hospital, Cagliari, Italy

    Giovanni Caocci

  12. Department of Hematology, “Spirito Santo” Hospital, Pescara, Italy

    Gaetano La Barba

  13. Ematologia, Azienda Ospedaliera S. Carlo, Potenza, Italy

    Michele Pizzuti

  14. Unit of Clinical Epidemiology, CPO Piemonte, AOU Città della Salute e della Scienza di Torino, Torino, Italy

    Giovannino Ciccone

  15. Divisione Universitaria di Ematologia e Terapie Cellulari, A.O. Ordine Mauriziano, Turin, Italy

    Giuseppe Saglio

  16. Hematology Section, Department of Emergency and Transplantation - GIMEMA WP CML, University of Bari Aldo Moro, Bari, Italy

    Giorgina Specchia

Authors
  1. Massimo Breccia
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Patrizia Pregno
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Fausto Castagnetti
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Massimiliano Bonifacio
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Mario Tiribelli
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Antonella Gozzini
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Anna Rita Scortechini
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Luigiana Luciano
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Bruno Martino
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Fabio Stagno
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Giovanni Caocci
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Gaetano La Barba
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Michele Pizzuti
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. Giovannino Ciccone
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. Giuseppe Saglio
    View author publications

    You can also search for this author in PubMed Google Scholar

  16. Giorgina Specchia
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Massimo Breccia.

Ethics declarations

Conflict of interest

MB received honoraria from Novartis, Incyte, Pfizer, BMS/Celgene, AbbVie; PP received honoraria from Novartis, Incyte, Pfizer; FC received honoraria from Novartis, BMS, Pfizer, Incyte; GS received honoraria from Novartis, Incyte, Pfizer; all the others declare no conflict of interest

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Breccia, M., Pregno, P., Castagnetti, F. et al. Eutos long-term survival score discriminates different Sokal score categories in chronic myeloid leukemia patients, showing better survival prediction. Analysis of the GIMEMA CML observational study. Leukemia 35, 1814–1816 (2021). https://doi.org/10.1038/s41375-021-01292-4

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41375-021-01292-4

  • Springer Nature Limited

This article is cited by

Search

Navigation